Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the 12 Stocks with Consistent Growth to Invest In. Following a strong positive second quarter, the company lowers its full-year guidance and announces the NDA acceptance for a new drug by the FDA. Corcept Therapeutics Beats Q2 Estimates, Cuts Guidance and Advances NDA for New Cancer Drug Corcept Therapeutics Incorporated (NASDAQ:CORT) reported its Q2 2025 earnings on July 31, 2025, in which it highlighted a 45% EPS beat, achieving $0.29 per share ...